#18V-18
Additive to improve immunogenicity in the inactivated BVDV vaccine

Live vaccines are more immunogenic than inactivated and recombinant vaccines, this is due to the presence of signals that pathogens express in the immune system when they replicate inside the individual. The presence of these signals could make inert vaccines as effective as live ones.

Presently, the market demands vaccine formulations that enable high protective responses, reducing management risks and stability during marketing and application.

INTA Virology Institute has developed **an additive** that enables to induce the **microbial viability signals system** to the **inactivated vaccine** against **the bovine viral diarrhea virus (BVDV)**, obtaining an inactivated vaccine with immunogenic response equivalent to live vaccines.

ADVANTAGES:

- Increased protective response of the inactivated vaccine against BVDV
- Applicable to different vaccine formulations
- Increased immunity duration
- Safe during pregnancy

TECHNOLOGY READINESS LEVEL:

In vitro concept tests with laboratory animal models performed with the additive-inactivated BVDV vaccine. Financing is required for testing in bovine cattle, scaling and marketing.

INTELLECTUAL PROPERTY RIGHTS STATUS: Additive and vaccine antigen qualify for invention patent protection.

DNA de Vinculación Tecnológica y Relaciones Institucionales - National Coordination Office for Technological Cooperation and Institutional Relations, INTA . Intellectual Property Department-Technological Antenna
Dr. Mariana Nanni nanni.mariana@inta.gob.ar

INTA

Ministerio de Agricultura, Ganadería y Pesca
Argentina